At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 434 enrolled
Drug / intervention
Secukinumabbiological
Likely dose
Secukinumab 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 24-week, Multicenter, proSpective stUdy to Evaluate the PASI 90 Clinical Response Rate and the Safety PRofile of sEcukinuMab 300 mg in Cw6-negativE and Cw6-positive Patients With Moderate to Severe Chronic Plaque-type Psoriasis (SUPREME)
In Brief
A Phase 3 clinical trial evaluating Secukinumab for Plaque Type Psorisis. Completed, enrolled 434 participants across 45 sites.
Detailed Summary
A study to evaluate the differences in the efficacy and safety of secukinumab between Cw6-negative and Cw6-positive patients with moderate to severe plaque-type psoriasis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlaque Type Psorisis
CountriesItaly
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 2015
Enrollment StartApr 2015
Primary CompletionJun 2017
TodayJul 2026
First PostedMar 20, 2015
Enrollment StartApr 10, 2015
Primary CompletionJun 8, 2017
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 11.3 years ago
Interventions
Secukinumabbiological
Secukinumab was supplied as 150 mg solution in pre-filled syringe for subcutaneous injection